Oncology Clinical Trial Swimmer Plot Data
Source:R/data_swimmer_unified_docs.R
swimmer_unified_oncology.Rd
A realistic oncology clinical trial dataset demonstrating comprehensive swimmer plot analysis for regulatory submissions. Includes detailed clinical milestones, tumor characteristics, and biomarker information.
Usage
data(swimmer_unified_oncology)
Format
A data frame with 20 rows and 12 variables:
- PatientID
Character. Unique patient identifiers (PT001-PT020)
- StartTime
Numeric. Treatment start time (all patients start at 0)
- EndTime
Numeric. Treatment end time in months (8-54 months)
- BestResponse
Character. Best overall response per RECIST (CR, PR, SD, PD)
- Surgery
Numeric. Time of surgery in months (1-7 months, NA if no surgery)
- Biopsy
Numeric. Time of biopsy in months (0-4 months)
- FirstResponse
Numeric. Time of first documented response (6-24 months, NA if no response)
- Progression
Numeric. Time of disease progression (6-36 months, NA if no progression)
- DeathLastFU
Numeric. Time of death or last follow-up (8-30 months, NA if alive)
- TumorType
Character. Primary tumor type (Lung, Breast, Melanoma, Colon, Liver)
- Stage
Character. Disease stage (IIA, IIB, IIIA, IIIB, IV)
- Biomarker
Character. Relevant biomarker status (PD-L1+, HER2+, BRAF+, etc.)
See also
Other swimmer plot datasets:
swimmer_unified_basic
,
swimmer_unified_comprehensive
,
swimmer_unified_datetime
,
swimmer_unified_events
Examples
data(swimmer_unified_oncology)
# Comprehensive oncology swimmer plot
swimmerplot(
data = swimmer_unified_oncology,
patientID = "PatientID",
startTime = "StartTime",
endTime = "EndTime",
responseVar = "BestResponse",
milestone1Name = "Surgery",
milestone1Date = "Surgery",
milestone2Name = "Biopsy",
milestone2Date = "Biopsy",
milestone3Name = "First Response",
milestone3Date = "FirstResponse",
milestone4Name = "Progression",
milestone4Date = "Progression",
milestone5Name = "Death/Last FU",
milestone5Date = "DeathLastFU",
referenceLines = "protocol",
showInterpretation = TRUE,
personTimeAnalysis = TRUE,
responseAnalysis = TRUE,
plotTheme = "ggswim",
sortOrder = "duration_desc"
)
#>
#> SWIMMER PLOT
#>
#> character(0)
#>
#> Timeline Summary Statistics
#> ───────────────────────────────────
#> Metric Value
#> ───────────────────────────────────
#> Number of Patients 20.00000
#> Total Observations 20.00000
#> Median Duration 31.50000
#> Mean Duration 30.80000
#> Total Person-Time 616.00000
#> Mean Follow-up 30.80000
#> CR Rate (%) 30.00000
#> PD Rate (%) 25.00000
#> PR Rate (%) 25.00000
#> SD Rate (%) 20.00000
#> ───────────────────────────────────
#>
#>
#> <div style='background-color: #e8f5e8; padding: 15px; border-radius:
#> 5px; margin: 10px 0;'>
#>
#> Clinical Interpretation
#>
#> <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Timeline
#> Analysis:
#>
#> Study included 20 patients with 20 timeline observations. Median
#> follow-up was 31.5 months (range: 8.0 to 54.0 months).
#>
#> <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Person-Time
#> Analysis:
#>
#> Total person-time: 616.0 months. Average follow-up per patient: 30.8
#> months.
#>
#> <div style='margin: 10px 0;'><h5 style='color: #2e7d32;'>Response
#> Pattern Analysis:
#>
#> Most common response was CR (30.0% of observations). Response
#> distribution shows clinical patterns suitable for efficacy analysis.
#>
#> Person-Time Analysis
#> ──────────────────────────────────────────────────────────────────────────
#> Response Type Patients Total Time Mean Time Incidence Rate
#> ──────────────────────────────────────────────────────────────────────────
#> ──────────────────────────────────────────────────────────────────────────
#>
#>
#> Milestone Event Summary
#> ────────────────────────────────────────────────────
#> Milestone Events Median Time Time Range
#> ────────────────────────────────────────────────────
#> ────────────────────────────────────────────────────
#>
#>
#> Advanced Clinical Metrics
#> ──────────────────────────────────────────────────────
#> Metric Value Unit Clinical Interpretation
#> ──────────────────────────────────────────────────────
#> ──────────────────────────────────────────────────────
#>